Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorPalacios-Garrán, Roberto
dc.contributor.authorLlorca-Bofí, Vicent
dc.contributor.authorArteaga Henriquez, Gara
dc.contributor.authordel Agua, Enrique
dc.date.accessioned2022-09-08T08:29:35Z
dc.date.available2022-09-08T08:29:35Z
dc.date.issued2022-05
dc.identifier.citationPalacios-Garrán R, Llorca-Bofí V, Arteaga-Henriquez G, del Agua E. Cariprazine Use in Combination With a Mood Stabilizer in First Episode Mania. Front Psychiatry. 2022 May;13:828088.
dc.identifier.issn1664-0640
dc.identifier.urihttp://hdl.handle.net/11351/8065
dc.descriptionAcute mania; Cariprazine; Precision medicine
dc.description.abstractBackground: Cariprazine's efficacy and safety have been previously tested in adult patients with acute mania associated with bipolar I disorder, but there is no available data in FEM. The objective of this study is to assess the efficacy and safety of cariprazine in combination with a mood stabilizer in treating FEM as well as to evaluate patients' adherence to the treatment. Methods: FEM patients were recruited from the acute inpatient unit at Lleida University Hospital Santa Maria, between January and June 2021. Their symptoms were evaluated using the Young Mania Rating Scale (YMRS) and the Clinical Global Impressions–Severity (CGI-S) scale at admission and at discharge. Akathisia was assessed using the Barnes Akathisia Rating Scale. Patient adherence to medication treatment was assessed 30 days after discharge using the Morisky, Green and Levine Medication Adherence Scale. Socio-demographic and clinical information were further collected. Results: Eleven patients with FEM were involved, seven women and four men. Their mean age was 26.00+/-6.37 years. Mean hospitalization was 17.36+/−4.7 days. Cariprazine was combined with a mood stabilizer: lithium in seven patients and divalproex in four. Mean YMRS change from baseline was −24.55+/−7.5 and the mean CGI-S change from baseline was −2.55+/−0.82. Regarding adverse events, two (18.2%) patients presented with akathisia. At the 30-day treatment-adherence assessment, six (54.5%) patients were adherent and four (36.4%) had moderate adherence. Conclusion: In this sample, cariprazine in combination with mood stabilizers proved to be safe and effective in the treatment of FEM with more than half the patients being adherent to treatment. Therefore, cariprazine add-on is a good choice for promoting the long-term adherence of patients, thus minimizing the risk of relapse and improving prognosis.
dc.language.isoeng
dc.publisherFrontiers Media
dc.relation.ispartofseriesFrontiers in Psychiatry;13
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectAvaluació de resultats (Assistència sanitària)
dc.subjectMania - Tractament
dc.subjectTrastorn bipolar - Diagnòstic
dc.subject.meshTreatment Outcome
dc.subject.meshAkathisia, Drug-Induced
dc.subject.meshBipolar Disorder
dc.subject.mesh/diagnosis
dc.titleCariprazine Use in Combination With a Mood Stabilizer in First Episode Mania
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.3389/fpsyt.2022.828088
dc.subject.decsresultado del tratamiento
dc.subject.decsacatisia inducida por medicamentos
dc.subject.decstrastorno bipolar
dc.subject.decs/diagnóstico
dc.relation.publishversionhttps://doi.org/10.3389/fpsyt.2022.828088
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Palacios-Garrán R, Llorca-Bofí V, del Agua E] Department of Psychiatry, Mental Health, and Addiction, GSS–Hospital Santa Maria, Lleida, Spain. [Arteaga-Henriquez G] Department of Psychiatry, Mental Health, and Addiction, GSS–Hospital Santa Maria, Lleida, Spain. Servei de Psiquiatria, Vall d'Hebron Hospital Universitari, Barcelona, Spain. Unitat de Genètica Psiquiàtrica, Grup de Recerca de Psiquiatria, Salut Mental i Addicions, Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Biomedical Network Research Center on Mental Health (CIBERSAM), Madrid, Spain. Departament de Psiquiatria i Medicina Forense, Universitat Autònoma de Barcelona, Bellaterra, Spain
dc.identifier.pmid35633804
dc.identifier.wos000804020300001
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record